Stopped Ozempic but the Stomach Symptoms Stayed? You Can Still File — the Clock Runs From Diagnosis, Not Your Last Dose

Stopping Ozempic does not end your right to file a claim. In most states the filing deadline runs from when you reasonably connected your symptoms to the drug, not from your last dose — and for some patients the stomach symptoms at the centre of these cases never went away after stopping.

For a plain-language explainer of everyday legal and money topics, see the Problem Solved channel.

  • Gastrointestinal injury cases are consolidated as MDL No. 3094 before Judge Karen S. Marston in the Eastern District of Pennsylvania.
  • Vision-loss claims sit in a separate MDL, No. 3163, before the same judge.
  • More than 4,000 cases sit across the two MDLs, and no global settlement has been announced.
  • Gastroparesis means delayed stomach emptying without a mechanical blockage; its symptoms include nausea, vomiting food eaten hours or days earlier, abdominal pain, and early satiety.
  • A September 2026 hearing addressed scientific-evidence issues that apply across the gastrointestinal cases.

Why Stopping the Drug Changes Nothing About Eligibility

Eligibility in the GLP-1 litigation has two pillars: use and injury. The first asks whether you took a covered drug, semaglutide sold as Ozempic, Wegovy, or Rybelsus, or tirzepatide sold as Mounjaro or Zepbound. The second asks whether you developed a qualifying injury, principally gastroparesis, the severe slowing or stopping of stomach emptying, or ileus, a blockage-like failure of the intestines to move. Neither pillar asks whether you are still taking the drug today. In fact, persistence after stopping is part of the plaintiffs' core argument: these drugs slow the stomach on purpose, through the GLP-1 hormone pathway, and the lawsuits allege that for a smaller group of patients the slowing became severe and did not resolve when the drug stopped. A patient who quit in 2024 and still cannot keep a meal down in 2026 is not a weaker claimant for having quit; on the facts alleged, that patient is the case. For the full list of qualifying injuries, read the Ozempic gastroparesis eligibility guide.

The Discovery Rule: Your Clock Starts at Connection, Not at the First Dose

Every state sets its own statute of limitations, the legal deadline for filing a claim, and for drug injuries most states apply the discovery rule. Under that rule the clock typically starts when you discovered, or reasonably should have discovered, that the drug caused your injury, not when you swallowed the first dose or took the last one. That distinction rescues many stopped patients: a person who took Ozempic in 2023, stopped in 2024, and received a gastroparesis diagnosis in 2025 may have a clock that started in 2025, when the diagnosis connected the symptoms to the drug. But the rule cuts both ways. A patient who was told in 2023 that the drug was likely causing the vomiting, then waited years, may find the clock started at that warning, not at a later formal diagnosis. Deadlines vary by state, from one year in some states to several in others, and court orders inside the MDL can set their own dates, so the only safe assumption is that your clock is already running. Note the date you first connected symptoms to the drug, keep the message or note where a doctor raised the link, and do not assume stopping paused anything.

The Symptom That Persists After the Last Dose

Understanding gastroparesis explains why "but I stopped" misses the point. A healthy stomach empties a meal within hours; a gastroparesis stomach stalls it, producing chronic nausea, vomiting of food eaten hours or even days earlier, severe abdominal pain, bloating, and early satiety, the feeling of fullness after a few bites. For most GLP-1 patients the slowing is tolerable and fades. For the patients in these cases it became a condition: hospital visits, dehydration, feeding difficulties, and a daily life organised around what the stomach will tolerate. That persistence is exactly what the lawsuits allege the original labels understated. It also explains the evidence fight now running through the MDL: whether a clinical diagnosis plus hospital records suffices, or whether a gastric emptying study, the test that measures how slowly the stomach actually empties, is required to prove the injury. Either way, a patient whose symptoms continued after the last dose holds the most important fact in the case, a timeline that shows the injury outlived the prescription.

The Evidence That Matters Most After You Stop

Stopping creates one evidence problem worth solving early: pharmacy records fade into archives. Request your complete dispensing history now, covering every GLP-1 prescription, its dose changes, and its stop date, because the defence will ask for a precise use timeline and gaps invite doubt. Next, assemble the diagnosis file: gastroenterology notes, emergency visits for vomiting or dehydration, any gastric emptying study, and records of dietary changes or procedures. Third, preserve the connection evidence: the date a doctor first suggested the drug as the cause, and any message where you raised the link yourself. Fourth, keep a simple symptom diary from today forward, even a few lines a week, because it documents persistence after stopping better than memory will a year from now. Patients who switched between drugs should list every product, since the MDL covers five named drugs across two manufacturers, and the full comparison is set out in the GLP-1 drugs-named guide. None of this requires you to still be taking anything; it requires you to prove what you took, when you stopped, and what stayed wrong.

Where the Litigation Stands Now

The gastrointestinal cases are consolidated as MDL No. 3094 before Judge Karen S. Marston in the Eastern District of Pennsylvania, a multidistrict litigation, the federal mechanism that groups individual lawsuits for shared pretrial steps while keeping each plaintiff's case separate. Vision-loss claims, alleging a sudden form of blindness called NAION, sit in a separate MDL, No. 3163, before the same judge. Together the two MDLs hold more than 4,000 cases, and a multi-day hearing in September 2026 addressed the scientific-evidence questions that apply across the gastrointestinal cases. No global settlement has been announced, and no payout figure can honestly be quoted yet; compensation, if it comes, will vary widely by case, and most settlements in mass litigation are confidential in any event. Stopped patients should read that status as a window, not a promise: the litigation is mature enough to have rules and hearings, but early enough that a well-documented claim still enters an active process. The latest case count and hearing outcome are tracked in the October 2026 Ozempic status update.

Who Benefits From This — and Who Does Not

Patients with a documented gastroparesis or ileus diagnosis, pharmacy records showing GLP-1 use, and symptoms that persisted after the last dose benefit most, because their records answer the two questions defendants ask first: did you take the drug, and did the injury last. Patients diagnosed only after stopping benefit too, because the discovery rule may place their deadline later than they feared, and patients who stopped on a doctor's advice benefit because the medical record itself documents the concern. Who does not benefit? Patients whose stomach symptoms were brief, resolved fully, and were never diagnosed as gastroparesis or ileus usually gain little, since the litigation centres on severe, lasting injuries rather than ordinary nausea. Patients who took only a compounded product face a different liability question, because the defendants and the supply chain differ. And patients whose state's deadline has already run cannot revive a claim by re-reading the clock; stopping does not pause it, and neither does wishing it had started later. The honest test is simple: a real diagnosis, a real drug history, and a clock that is still open.

Frequently Asked Questions

Can I still file an Ozempic lawsuit after I stopped taking it?

Yes. Stopping the drug does not end eligibility. The cases turn on whether you took a GLP-1 drug and developed a qualifying injury, not on whether you are still taking it, and for some patients the stomach symptoms at the centre of these cases never resolved after stopping.

Who benefits most from filing after stopping?

Patients with a documented gastroparesis or ileus diagnosis, pharmacy records showing GLP-1 use, and symptoms that persisted after the last dose benefit most, because their records answer the two questions defendants ask first: did you take the drug, and did the injury last. Patients whose diagnosis came only after stopping also benefit, because the discovery rule may place their deadline later than they feared.

Who does not benefit from an Ozempic claim?

Patients whose stomach symptoms were brief, resolved fully, and were never diagnosed as gastroparesis or ileus usually gain little, because the litigation centres on severe, lasting injuries. Patients who took only a compounded product with no brand-drug history face a different liability question, and patients whose state's deadline has already run out cannot revive a claim by re-reading the clock.

How do I start an Ozempic claim after stopping?

First, request your pharmacy dispensing records for every GLP-1 prescription, including start and stop dates. Second, gather the diagnosis records: gastroparesis or ileus findings, gastric emptying study results if one was done, and hospital records. Third, write down when you first connected the symptoms to the drug, since that date often starts the filing clock. Fourth, speak to a mass-tort attorney promptly, because deadlines vary by state and court orders in the MDL can set their own dates.

What if my gastroparesis was never confirmed by a gastric emptying study?

A gastric emptying study is the test that measures how slowly the stomach empties, and it is the strongest documentation of gastroparesis. Courts in the MDL have been testing what proof suffices, so a clinical diagnosis with hospital records may still support a claim, but a study removes the argument entirely. Ask your doctor whether one is appropriate for you.

Where does the Ozempic litigation stand now?

Gastrointestinal injury cases are consolidated as MDL No. 3094 before Judge Karen S. Marston in the Eastern District of Pennsylvania, with a separate MDL, No. 3163, for vision-loss claims. More than 4,000 cases sit across the two MDLs, a September 2026 hearing addressed scientific-evidence issues, and no global settlement has been announced.

This article is general information about litigation, not legal or medical advice. Filing deadlines and medical questions are individual, so speak to a qualified attorney and your doctor about your own situation.

Watch on YouTube

Problem Solved on YouTube